Detection of C677T, rs75582903 and SNV64878785 in Methylenetetra hydrofolate Reductase Gene (MTHFR) in Meningioma among Sudanese patients
Introduction: Meningiomas are commonly benign tumors come from the arachnoid cap cells, and the incidence is account 6 cases per 1000000 of population per year or even much higher in African countries, in Sudan during the period May 2005-May 2012 a total of 405 patients were operated upon and diagnosed as having cranial meningioma, regarding the etiologies of meningiomas are not yet known; it may be related to radiation exposure, genetic disorders (Neurofibromatosis type2), hormonal imbalance (progesterone) and single nucleotide polymorphisms (SNPs).
Aims of the study: This study aimed to amplify MTHFR gene in specific region using PCR, and to detect C677T, rs755829023 and SNV64878785 of MTHFR gene in meningioma among Sudanese patients.
Materials and Methods: This was a cross-sectional study conducted at the National Center for Neurological Sciences between May to August 2022, Khartoum Sudan, all meningioma patients attending the national center of neurological sciences during the period of the study was included. Demographic variables were included (age and gender), and the clinical data included (meningioma histology subtype and WHO grading), tissue and blood samples were collected, DNA extraction from the tissue and blood samples was done, polymerase chain reaction was made to amplify specific region of MTHFR gene. PCR products were sent for Sanger sequencing to Macrogen Europe Laboratory. Data was collected and analyzed by using Statistical Package for the Social Sciences (SPSS) version 19, and sequencing was analyzed using, BioEdit and Mutation taster.
Results: In this study the most affected age group was 41-50 years, female was the most common, WHO grade I meningioma constituted 70% of the cases mostly the fibrous subtype. C>T (g.10369 C>T) was detected in 100% of the cases and deletion C (g.10380-10380delC) was detected only in the cases 16.6%.
Conclusion: In this study, female was the most common 11(55%) with male to female ratio 1:2, the most affected age group was ranging from 41-50 years constituted 35%, WHO grade I meningioma was detected in 70% of the patients. C>T (g.10369 C>T) was detected in 100% of the cases and deletion C (g.10380-10380delC) was detected only in the cases 16.6%.
2. Aldeaf S A H, Gassoum A, Arbab M A R, et al. Expression of stem cell markers in meningioma among Sudanese patients. Research Results In Biomedicine. 2022; 8(1):5-14. https://doi.org/10.18413/2658-6533-2022-8-1-0-1
3. Arbab M A, Al deaf S A, El Hassan L A, Beshir B M, Ahmed M S, Mohamed H A, Elhassan, A M. Cranial Meningioma in Sudanese Patients: Clinical and Pathological Characteristics. Int J Res IJR, 2014; 1.
4. Javaid A, Wattoo B, Abid R and Sadaf S. Analysis of Functional Polymorphisms in Meningioma associated Genes. Current Trends in OMICS, 2021; 1(2):1-35. https://doi.org/10.32350/cto.12.01
5. Huntoon K, Toland A M S, Dahiya S. Meningioma: A Review of Clinicopathological and Molecular Aspects. Front Oncol, Oct 2020; 23(10):579599. https://doi.org/10.3389/fonc.2020.579599
6. Riemenschneider M J, Perry A and Reifenberger G. Histological classification and molecular genetics of meningiomas. The Lancet Neurology, 2006; 5(12):1045-1054. https://doi.org/10.1016/S1474-4422(06)70625-1
7. Li R, Wang R, Li Y, Li X, Feng Y, Li Y and Jiang C. Association study on MTHFR polymorphisms and meningioma in northern China. Journal Gene. 2013; 516(2):291-293. https://doi.org/10.1016/j.gene.2012.12.019
8. Ding H, Liu W, Yu X, Wang L, and Shao L, Yi W. Risk association of meningiomas with MTHFR C677T and GSTs polymorphisms: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014; 7(11):390-14.
9. Bastos C, do Nascimento Borges B, Diniz I, Brito J, Anselmo N, Pieczarka J, Nagamachi C. MTHFR C677T polymorphism not associated with meningiomas: Study of an interethnic Brazilian population and meta-analysis. Meta Gene, 2020; 26:100795. https://doi.org/10.1016/j.mgene.2020.100795
10. Chen Xu, Lutao Yuan, Hengl, Tian, Heli Cao, Shiwen Chen. Association of the MTHFR C677T polymorphism with primary brain tumor risk. Tumor Biology, 2013; 34(6):3457-64. DOI: 10.1007/s13277-013-0922-9 https://doi.org/10.1007/s13277-013-0922-9
11. Fathi AR, Roelcke U. Meningioma. Curr Neurol Neurosci Rep, 2013; 13:337 https://doi.org/10.1007/s11910-013-0337-4
12. Wiemels J, Wrensch M, Claus E B. Epidemiology and etiology of meningioma. J Neurooncol, Sep 2010; 99(3):307-14. https://doi.org/10.1007/s11060-010-0386-3
13. Berry R J, Bailey L, Mulinare J, Bower C, Dary O. Fortification of Flour with Folic Acid. Food Nutr. Bull. 2010; 31:S22-S35. https://doi.org/10.1177/15648265100311S103
14. Ebara S. Nutritional role of folate. Congenit. Anom, 2017; 57:138-141. https://doi.org/10.1111/cga.12233
15. Salazar M D, Ratnam M. The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev, 2007; 26:141-152. https://doi.org/10.1007/s10555-007-9048-0
16. Stover P J. One-Carbon Metabolism-Genome Interactions in Folate-Associated Pathologies. J. Nutr, 2009; 139:2402-2405. https://doi.org/10.3945/jn.109.113670
17- Bailey LB, Stover P J, McNulty H, Fenech MF, Gregory J F, Mills J.L, Pfeiffer CM, Fazili Z, Zhang M, Ueland PM, et al. Biomarkers of Nutrition for Development-Folate Review. J. Nutr, 2015; 145:1636S-1680S. https://doi.org/10.3945/jn.114.206599
18. Duthie S J, Narayanan S, Brand G M, Pirie L, Grant G. Impact of Folate Deficiency on DNA Stability. J. Nutr, 2002; 132:2444S-2449S. https://doi.org/10.1093/jn/132.8.2444S
19. Berger S H, Pittman D L, Wyatt M D. Uracil in DNA: Consequences for carcinogenesis and chemotherapy. Biochem Pharmacol, 2008; 76(6):697-706. https://doi.org/10.1016/j.bcp.2008.05.019
20. Bethke L, Webb E, Murray A, Schoemaker M, Feychting M, Lönn S, Ahlbom A, Malmer B, Henriksson R, Auvinen A, et al. Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma. Cancer Epidemiol. Biomark. Prev, 2008; 17:1195-1202. https://doi.org/10.1158/1055-9965.EPI-07-2733
21. Hasan T, Arora R, Bansal A K, Bhattacharya R, Sharma GS, Singh L R. Disturbed homocysteine metabolism is associated with cancer. Exp. Mol. Med, 2019; 51:1-13. https://doi.org/10.1038/s12276-019-0216-4
22. Tsang B L, Devine O J, Cordero A M, Marchetta C M, Mulinare J, Mersereau P, Guo J, Qi Y P, Berry R J, Rosenthal J, et al. Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: A systematic review and meta-analysis of trials and observational studies. Am. J. Clin. Nutr, 2015; 101:1286-1294. https://doi.org/10.3945/ajcn.114.099994
23. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer, 2009; 45:1333-1351. https://doi.org/10.1016/j.ejca.2008.12.004
24. Farkas S A, Böttiger A K, Isaksson H S, Finnell R H, Ren A, Nilsson T K, Nilsson T K. Epigenetic alterations in folate transport genes in placental tissue from fetuses with neural tube defects and in leu-kocytes from subjects with hyperhomocysteinemia. Epigenetics, 2013; 8:303-316. https://doi.org/10.4161/epi.23988
25. Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, Chan M , Rozen R. Gene structure of human and mouse Methylenetetrahydrofolate reductase (MTHFR). Mamm. Genome, 1998; 9:652-656. https://doi.org/10.1007/s003359900838
26. Semmler A, Simon M, Moskau S, Linnebank M. Polymorphisms of methionine metabolism and susceptibility to meningioma formation: Laboratory investigation. J. Neurosurg, 2008; 108:999-1004. https://doi.org/10.3171/JNS/2008/108/5/0999
27. Hickey S E, Curry C J, Toriello H V. ACMG Practice Guideline: Lack of evidence for MTHFR polymorphism testing.Genet. Med, 2013; 15:153-156. https://doi.org/10.1038/gim.2012.165
28. Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, Seligsohn U. The frequent 5, 10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplo-type in whites, Japanese, and Africans.Am. J. Hum. Genet, 2002; 70:758-762. https://doi.org/10.1086/338932
29. Robien K, Ulrich C M. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview. Am. J. Epidemiol, 2003; 157:571-582. https://doi.org/10.1093/aje/kwg024
30. Yang Q H, Botto L D, Gallagher M, Friedman J M, Sanders CL., Koontz D, Nikolova S, Erickson J D, Steinberg K. (2008). Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: Findings from the third National Health and Nutrition Examination Survey DNA Bank. Am. J. Clin. Nutr, 2008; 88:232-246. https://doi.org/10.1093/ajcn/88.1.232
31. Liew SC, Gupta E D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases. Eur. J. Med. Genet, 2015; 58:1-10. https://doi.org/10.1016/j.ejmg.2014.10.004
32. Levin B L, Varga E. MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature. J. Genet. Couns, 2016; 25:901-911. https://doi.org/10.1007/s10897-016-9956-7
33. Bolufer P, Barragán E, Collado M, Cervera J, Lopez J A, Sanz MA. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk. Res, 2006; 30:1471-1491. https://doi.org/10.1016/j.leukres.2006.01.016
34. Kim H N, Lee I, Kim Y, Tran H T , Yang D, Lee J, Shin M, Park K, Shin M, Choi J, et al. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br. J. Haematol, 2007; 140:287-294. https://doi.org/10.1111/j.1365-2141.2007.06893.x
35. Tang M, Wang S Q, Liu B J, Cao Q, Li B J, Li P C, Li YF, Qin C, Zhang W. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: Evidence from 134 case-control studies. Mol. Biol. Rep, 2014; 41:4659-73. https://doi.org/10.1007/s11033-014-3337-9
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).